Piper Jaffray downgraded Myriad Genetics (NASDAQ: MYGN) from Overweight to Neutral with a price target of $22.00 (from $47.00).Analyst William ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst EPS View Analyst PT Change Downgrades

Jefferies Remains Sidelined on Myriad Genetics (MYGN) Following 4Q August 11, 2016 8:37 AM Mizuho Securities Cuts Price Target on Myriad Genetics (MYGN) to $22 Following 4Q and Guidance August 10, 2016 7:19 AM Wells Fargo Downgrades Myriad Genetics (MYGN) to Market PerformAugust 10, 2016 7:03 AM Myriad Genetics (MYGN) Misses Q4 EPS by 6c; Issues Weak Q1, FY17 OutlookAugust 9, 2016 4:11 PM Myriad Genetics Reports Fiscal Fourth-Quarter 2016 Financial ResultsAugust 9, 2016 4:06 PM